[go: up one dir, main page]

BR0110302A - Compostos de pirazol para inibição de proteìnas cinase, sal e pró-droga farmaceuticamente aceitável, metabólito farmaceuticamente ativo ou sal farmaceuticamente aceitável de metabólito, composição farmacêutica, método de tratamento de condição doentia em mamìferos mediada pela atividade de proteìna cinase, método de modulação ou inibição da atividade de um receptor de proteìna cinase - Google Patents

Compostos de pirazol para inibição de proteìnas cinase, sal e pró-droga farmaceuticamente aceitável, metabólito farmaceuticamente ativo ou sal farmaceuticamente aceitável de metabólito, composição farmacêutica, método de tratamento de condição doentia em mamìferos mediada pela atividade de proteìna cinase, método de modulação ou inibição da atividade de um receptor de proteìna cinase

Info

Publication number
BR0110302A
BR0110302A BR0110302-4A BR0110302A BR0110302A BR 0110302 A BR0110302 A BR 0110302A BR 0110302 A BR0110302 A BR 0110302A BR 0110302 A BR0110302 A BR 0110302A
Authority
BR
Brazil
Prior art keywords
protein kinase
activity
pharmaceutically acceptable
acceptable salt
metabolite
Prior art date
Application number
BR0110302-4A
Other languages
English (en)
Inventor
Siegfried Heinz Reich
Michael B Wallace
Original Assignee
Agouron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agouron Pharma filed Critical Agouron Pharma
Publication of BR0110302A publication Critical patent/BR0110302A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"COMPOSTOS DE PIRAZOL PARA INIBIçãO DE PROTEìNAS CINASE, SAL E PRó-DROGA FARMACEUTICAMENTE ACEITáVEL, METABóLITO FARMACEUTICAMENTE ATIVO OU SAL FARMACEUTICAMENTE ACEITáVEL DE METABóLITO, COMPOSIçãO FARMACêUTICA, MéTODO DE TRATAMENTO DE CONDIçãO DOENTIA EM MAMìFEROS MEDIADA PELA ATIVIDADE DE PROTEìNA CINASE, MéTODO DE MODULAçãO OU INIBIçãO DA ATIVIDADE DE UM RECEPTOR DE PROTEìNA CINASE". Compostos de amino-pirazol da fórmula (I), que modulam e/ou inibem a atividade de proteínas cinases. Estes compostos e composições farmacêuticas que os contêm são capazes de mediar e/ou inibir a atividade de cinases de ciclina-dependentes, de forma a modular e/ou inibir a proliferação celular indesejada. A presente invenção também se refere à utilização terapêutica ou profilática de composições farmacêuticas que contenham esses compostos e métodos de tratamento de câncer, bem como outros estados doentios associados à angiogênese e/ou proliferação celular indesejada, tais como retinopatia diabética, glaucoma neovascular, artrite reumatóide e psoríase, através da administração de quantidades eficazes desses compostos.
BR0110302-4A 2000-04-18 2001-04-05 Compostos de pirazol para inibição de proteìnas cinase, sal e pró-droga farmaceuticamente aceitável, metabólito farmaceuticamente ativo ou sal farmaceuticamente aceitável de metabólito, composição farmacêutica, método de tratamento de condição doentia em mamìferos mediada pela atividade de proteìna cinase, método de modulação ou inibição da atividade de um receptor de proteìna cinase BR0110302A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19786200P 2000-04-18 2000-04-18
PCT/US2001/010997 WO2001079198A1 (en) 2000-04-18 2001-04-05 Pyrazoles for inhibiting protein kinase

Publications (1)

Publication Number Publication Date
BR0110302A true BR0110302A (pt) 2003-01-14

Family

ID=22731040

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0110302-4A BR0110302A (pt) 2000-04-18 2001-04-05 Compostos de pirazol para inibição de proteìnas cinase, sal e pró-droga farmaceuticamente aceitável, metabólito farmaceuticamente ativo ou sal farmaceuticamente aceitável de metabólito, composição farmacêutica, método de tratamento de condição doentia em mamìferos mediada pela atividade de proteìna cinase, método de modulação ou inibição da atividade de um receptor de proteìna cinase

Country Status (13)

Country Link
US (1) US6462069B2 (pt)
EP (1) EP1274706A1 (pt)
JP (1) JP2004501083A (pt)
AR (1) AR030211A1 (pt)
AU (1) AU2001249865A1 (pt)
BR (1) BR0110302A (pt)
CA (1) CA2398446A1 (pt)
GT (1) GT200100061A (pt)
MX (1) MXPA02010222A (pt)
PA (1) PA8515701A1 (pt)
PE (1) PE20020226A1 (pt)
SV (1) SV2002000376A (pt)
WO (1) WO2001079198A1 (pt)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020150921A1 (en) * 1996-02-09 2002-10-17 Francis Barany Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
HRP20020547B1 (hr) 1999-12-24 2011-06-30 Aventis Pharma Limited Azaindoli
DZ3398A1 (fr) * 2000-08-31 2002-03-07 Pfizer Prod Inc Derives pyrazole et leur utilisation comme inhibiteurs des proteines kinases
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US7473691B2 (en) 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
CA2422367C (en) 2000-09-15 2010-05-18 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
WO2002059111A2 (en) 2000-12-21 2002-08-01 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6756374B2 (en) 2001-01-22 2004-06-29 Hoffmann-La Roche Inc. Diaminothiazoles having antiproliferative activity
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
EA008770B1 (ru) * 2002-05-15 2007-08-31 Янссен Фамацевтика Н.В. N-замещенные трициклические 3-аминопиразолы в качестве ингибиторов pdgf рецептора
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
EP1739087A1 (en) * 2002-08-02 2007-01-03 Vertex Pharmaceuticals Incorporated Pyrazole compositions useful as inhibitors of gsk-3
JP4733388B2 (ja) 2002-08-02 2011-07-27 バーテックス ファーマシューティカルズ インコーポレイテッド Ｇｓｋ−３のインヒビターとして有用なピラゾール組成物
US7157455B2 (en) 2003-02-10 2007-01-02 Hoffmann-La Roche Inc. 4-Aminopyrimidine-5-one derivatives
JP2006518368A (ja) * 2003-02-21 2006-08-10 ファイザー・インク プロテインキナーゼ阻害剤としてのｎ−ヘテロシクリル置換アミノチアゾール誘導体
WO2004076414A2 (en) 2003-02-27 2004-09-10 Smithkline Beecham Corporation Novel compounds
FR2854159B1 (fr) * 2003-04-25 2008-01-11 Aventis Pharma Sa Nouveaux derives de l'indole, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de kdr
TWI372050B (en) 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
US20050032869A1 (en) * 2003-07-08 2005-02-10 Pharmacia Italia S.P.A. Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
JP4681548B2 (ja) * 2003-07-22 2011-05-11 アステックス・セラピューティクス・リミテッド ３，４−ジ置換１ｈ−ピラゾール化合物および、そのサイクリン依存性キナーゼ（ｃｄｋ）およびグリコーゲン・シンセターゼ・キナーゼ−３（ｇｓｋ−３）調節剤としての使用
JP2006528661A (ja) * 2003-07-25 2006-12-21 ファイザー・インク アミノピラゾール化合物およびｃｈｋ１阻害剤としての使用
AU2004291503A1 (en) * 2003-11-13 2005-06-02 Janssen Pharmaceutica N.V. Immobilized N-substituted tricyclic 3-aminopyrazoles for the identification of biomolecular targets
GB0326601D0 (en) * 2003-11-14 2003-12-17 Novartis Ag Organic compounds
GB2410947B (en) * 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds
US7211576B2 (en) 2004-04-20 2007-05-01 Hoffmann-La Roche Inc. Diaminothiazoles
JP2007533717A (ja) * 2004-04-21 2007-11-22 アストラゼネカ アクチボラグ 化合物
US20060035920A1 (en) * 2004-05-28 2006-02-16 Millennium Pharmaceuticals, Inc. Chk-1 inhibitors
JP2008501628A (ja) * 2004-06-02 2008-01-24 武田薬品工業株式会社 インドール誘導体およびがんの治療用途
US7405220B2 (en) 2004-06-09 2008-07-29 Hoffmann-La Roche Inc. Pyrazolopyrimidines
US7423051B2 (en) 2004-07-15 2008-09-09 Hoffmann-La Roche Inc. 2,6-diaminopyridine derivatives
US7423053B2 (en) 2004-07-15 2008-09-09 Hoffmann-La Roche Inc. 4-Aminothiazole derivatives
BRPI0517737A (pt) * 2004-11-17 2008-10-21 Miikana Therapeutics Inc inibidores de quinase
CA2593993C (en) * 2004-12-30 2014-07-29 Astex Therapeutics Limited Pyrazole compounds that modulate the activity of cdk, gsk and aurora kinases
JP2008526723A (ja) * 2004-12-30 2008-07-24 アステックス、セラピューティックス、リミテッド Ｃｄｋ、ｇｓｋ及びオーロラキナーゼの活性を調節するピラゾール誘導体
WO2006101454A1 (en) * 2005-03-21 2006-09-28 S*Bio Pte Ltd Benzothiophene derivatives: preparation and pharmaceutical applications
GB0514501D0 (en) * 2005-07-14 2005-08-24 Cambridge Lab Ireland Ltd Pharmaceutical compounds
GB0516168D0 (en) * 2005-08-05 2005-09-14 Cambridge Lab Ireland Ltd Pharmaceutical compounds
BRPI0616630B8 (pt) * 2005-09-30 2021-05-25 Miikana Therapeutics Inc compostos de pirazol substituídos
BRPI0619706A2 (pt) 2005-11-03 2011-10-11 Vertex Pharma composto, composição, método para inibir a atividade da proteìna aurora quinase numa amostra biológica, método para tratar um distúrbio proliferativo num paciente, método para tratar cáncer num indivìduo
US7705009B2 (en) 2005-11-22 2010-04-27 Hoffman-La Roche Inc. 4-aminopyrimidine-5-thione derivatives
WO2007077435A1 (en) 2005-12-30 2007-07-12 Astex Therapeutics Limited Pharmaceutical compounds
US8212048B2 (en) 2006-02-03 2012-07-03 Sumitomo Chemical Company, Limited Method of producing aromatic compound
WO2008001115A2 (en) 2006-06-29 2008-01-03 Astex Therapeutics Limited Pharmaceutical combinations of 1-cyclopropyl-3- [3- (5-m0rphoolin-4-ylmethyl-1h-benzoimidazol-2-yl) -lh-1-pyrazol- 4-yl] -urea
JP2010529193A (ja) * 2007-06-11 2010-08-26 ミイカナ セラピューティクス インコーポレイテッド 置換ピラゾール化合物
AR071717A1 (es) 2008-05-13 2010-07-07 Array Biopharma Inc Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer.
GB0810857D0 (en) * 2008-06-13 2008-07-23 Cambridge Lab Ireland Ltd Pharmaceutical compounds
GB2462611A (en) * 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
US20110053866A1 (en) * 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
GB2463452A (en) * 2008-09-08 2010-03-17 Cambridge Lab Desmethyl derivatives of tetrabenazine and pharmaceutical compositions thereof
GB2463283A (en) * 2008-09-08 2010-03-10 Cambridge Lab 3,11b-cis-dihydrotetrabenazine for use in treating asthma
GB2463451A (en) 2008-09-08 2010-03-17 Cambridge Lab 3, 11b cis-dihydrotetrabenazine compounds for use in the treatment of dementia
CN103408540B (zh) * 2013-08-22 2016-05-18 中国药科大学 2-唑环取代噻吩类plk1抑制剂及其用途及其用途
CN108690006B (zh) * 2017-04-12 2022-02-18 中国药科大学 一类化合物及其在抗aml药物中的用途
AU2019217094B2 (en) 2018-02-07 2023-04-06 Industry-Academic Cooperation Foundation, Yonsei University Compounds for inhibiting TNIK and medical uses thereof
CN110835334B (zh) * 2018-08-16 2022-10-18 中国药科大学 吲哚取代唑类化合物及其用途
MX2023014028A (es) 2021-05-27 2023-12-12 Boundless Bio Inc Inhibidores de cinasa de punto de control 1 (chk1) y usos de los mismos.
TW202440549A (zh) * 2022-11-29 2024-10-16 美商無界生物公司 檢查點激酶１（ｃｈｋ１）抑制劑及其用途

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE273062C (de) 1912-04-19 1914-04-20 Deylen Sohn Firma Vorrichtung zum Schränken von Plattenzündspänen
CH575397A5 (pt) 1971-11-09 1976-05-14 Basf Ag
WO1986005779A1 (en) 1985-04-03 1986-10-09 Yamanouchi Pharmaceutical Co., Ltd. Phenylene derivatives
JPH083564B2 (ja) 1986-07-25 1996-01-17 三菱化学株式会社 偏光フィルム
DD273062A1 (de) 1988-06-14 1989-11-01 Fahlberg List Veb Verfahren zur herstellung von hydroxybenzoesaeure(chinoxalin-2-ylmethyl)-ethern und -estern
CA1330079C (en) * 1988-10-13 1994-06-07 Michihiko Tsujitani Pyrrolo (3,2-e)pyrazolo(1,5-a)pyrimidine derivative and medicine comprising the same
ES2108120T3 (es) 1991-05-10 1997-12-16 Rhone Poulenc Rorer Int Compuestos bis arilicos y heteroarilicos mono- y biciclicos que inhiben tirosina quinasa receptora de egf y/o pdgf.
EP0636123A1 (en) 1992-03-24 1995-02-01 MERCK SHARP & DOHME LTD. 3-ureido substituted benzodiazepin-2-ones having cholecystokinin and/or gastrin antagonistic activity and their use in therapy
US5612360A (en) 1992-06-03 1997-03-18 Eli Lilly And Company Angiotensin II antagonists
JPH08504798A (ja) 1992-12-18 1996-05-21 ザ ウエルカム ファウンデーション リミテッド 酵素阻害薬としての，ピリミジン，ピリジン，プテリジノンおよびインダゾール誘導体
US5625031A (en) 1994-02-08 1997-04-29 Bristol-Myers Squibb Company Peptide inhibitors of the p33cdk2 and p34cdc2 cell cycle regulatory kinases and human papillomavirus E7 oncoprotein
US5631156A (en) 1994-06-21 1997-05-20 The University Of Michigan DNA encoding and 18 KD CDK6 inhibiting protein
US5916908A (en) * 1994-11-10 1999-06-29 Cor Therapeutics, Inc. Pharmaceutical pyrazole compositions useful as inhibitors of protein kinases
AU699727B2 (en) 1995-02-02 1998-12-10 Smithkline Beecham Plc Indole derivatives as 5-HT receptor antagonist
US5710173A (en) 1995-06-07 1998-01-20 Sugen, Inc. Thienyl compounds for inhibition of cell proliferative disorders
WO1997003967A1 (en) 1995-07-22 1997-02-06 Rhone-Poulenc Rorer Limited Substituted aromatic compounds and their pharmaceutical use
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
US5705499A (en) 1995-10-06 1998-01-06 Boehringer Ingelheim Pharmaceuticals, Inc. 8-arylalkyl- and 8-arylheteroalkyl-5,11-dihydro-6H-dipyrido 3,2-B:2',3'-e! 1!diazepines and their use in the treatment of HIV-1 infection
US5733920A (en) 1995-10-31 1998-03-31 Mitotix, Inc. Inhibitors of cyclin dependent kinases
US5760028A (en) 1995-12-22 1998-06-02 The Dupont Merck Pharmaceutical Company Integrin receptor antagonists
US6495526B2 (en) 1996-01-23 2002-12-17 Gpc Biotech, Inc. Inhibitors of cell-cycle progression and uses related thereto
US6514971B1 (en) 1996-03-15 2003-02-04 Zeneca Limited Cinnoline derivatives and use as medicine
GB9608435D0 (en) 1996-04-24 1996-06-26 Celltech Therapeutics Ltd Chemical compounds
US5849733A (en) 1996-05-10 1998-12-15 Bristol-Myers Squibb Co. 2-thio or 2-oxo flavopiridol analogs
DE69709493T2 (de) 1996-06-27 2002-10-31 Pfizer Inc., New York Substituierte Indazolderivate
FR2750862B1 (fr) 1996-07-12 1998-10-16 Dupin Jean Pierre Utilisation d'heterocycles diazotes fusionnes avec un systeme aromatique ou heteroaromatique pour le traitement des maladies thrombo-emboliques
US5821243A (en) 1996-07-22 1998-10-13 Viropharma Incorporated Compounds compositions and methods for treating influenza
US6262040B1 (en) 1996-09-04 2001-07-17 Pfizer Inc Indazole derivatives and their use as inhibitors of phosphodiesterase (PDE) type IV and the production of tumor necrosis factor (TNF)
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
GB9621757D0 (en) 1996-10-18 1996-12-11 Ciba Geigy Ag Phenyl-substituted bicyclic heterocyclyl derivatives and their use
ES2301194T3 (es) 1997-02-05 2008-06-16 Warner-Lambert Company Llc Pirido 2,3-d pirimidinas y 4-aminopirimidinas como inhibidores de la proliferacion celular.
WO1998038168A1 (en) 1997-02-27 1998-09-03 Tanabe Seiyaku Co., Ltd. Isoquinolinone derivatives, process for preparing the same, and their use as phosphodiesterase inhibitors
CA2294244A1 (en) 1997-07-12 1999-01-21 Cancer Research Campaign Technology Limited Cyclin dependent kinase inhibiting purine derivatives
GB9716324D0 (en) 1997-08-01 1997-10-08 Mead Corp Packaging machine and method of carton set up
FR2767827A1 (fr) 1997-09-03 1999-02-26 Adir Nouveaux derives de l'indole et de l'indazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
WO1999017769A1 (en) 1997-10-06 1999-04-15 Basf Aktiengesellschaft INDENO[1,2-c]-, NAPHTHO[1,2-c]- AND BENZO[6,7]CYCLOHEPTA[1,2-c]PYRAZOLE DERIVATIVES
RO119463B1 (ro) 1997-10-27 2004-11-30 Agouron Pharmaceuticals, Inc. Derivaţi de 4-aminotiazol şi utilizarea lor ca inhibitori ai cdk
YU25400A (sh) 1997-11-04 2003-07-07 Pfizer Products Inc. Terapeutski aktivna jedinjenja sa indazolom
SK6252000A3 (en) 1997-11-04 2001-11-06 Pfizer Prod Inc Indazole bioisostere replacement of catechol in therapeutically active compounds
US6040321A (en) 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
AU748178B2 (en) 1998-02-26 2002-05-30 Aventis Holdings Inc. 6,9-disubstituted 2-(trans-(4- aminocyclohexyl) amino)purines
US6479487B1 (en) 1998-02-26 2002-11-12 Aventis Pharmaceuticals Inc. 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
YU46200A (sh) 1998-02-27 2003-02-28 Pfizer Products Inc. N-(supstituisani peto-članog di-ili triaza dinezasićenog prstena)karbonil/guanidin derivati za tretiranje ishemije
NZ507567A (en) 1998-04-21 2003-08-29 Du Pont Pharm Co 5-aminoindeno(1,2-c)pyrazol-4-ones as anti-cancer and anti-proliferative agents
ES2237919T4 (es) 1998-06-18 2007-05-01 Bristol-Myers Squibb Company Inhibidores aminotiazol sustituidos con carbono de quinasas dependientes de ciclina.
ES2211175T3 (es) 1998-09-29 2004-07-01 Wyeth Holdings Corporation Inhibidores de proteinas de tipo tirosina quinasas a base de 3-cianoquinolinas sustituidas.
EP1189609A4 (en) * 1999-05-03 2002-10-30 Smithkline Beecham Corp CXCR-4 RECEPTOR ANTAGONISTS AND THROMBOPOIETIN MIMETIKA

Also Published As

Publication number Publication date
AR030211A1 (es) 2003-08-13
US6462069B2 (en) 2002-10-08
JP2004501083A (ja) 2004-01-15
EP1274706A1 (en) 2003-01-15
PE20020226A1 (es) 2002-04-02
MXPA02010222A (es) 2003-05-23
CA2398446A1 (en) 2001-10-25
WO2001079198A1 (en) 2001-10-25
AU2001249865A1 (en) 2001-10-30
US20020006952A1 (en) 2002-01-17
WO2001079198A9 (en) 2002-05-16
PA8515701A1 (es) 2002-02-21
WO2001079198B1 (en) 2002-06-13
SV2002000376A (es) 2002-12-02
GT200100061A (es) 2002-03-14

Similar Documents

Publication Publication Date Title
BR0110302A (pt) Compostos de pirazol para inibição de proteìnas cinase, sal e pró-droga farmaceuticamente aceitável, metabólito farmaceuticamente ativo ou sal farmaceuticamente aceitável de metabólito, composição farmacêutica, método de tratamento de condição doentia em mamìferos mediada pela atividade de proteìna cinase, método de modulação ou inibição da atividade de um receptor de proteìna cinase
BR0107783A (pt) Compostos de indazol, seu sais farmaceuticamente aceitáveis, pró-drogas ou metabólitos farmaceuticamente ativos, composições farmacêuticas, método de tratamento de doenças ou disfunções mediadas pela inibição de um complexo de cinase, método de tratamento de doenças de mamìferos mediadas pela atividade de cinase, método de modulação ou inibição da atividade de um receptor de proteìna cinase, método de tratamento de estado doentio ou disfunção associada à proliferação celular descontrolada, composição farmacêutica para o tratamento de estado doentio associado a proliferaçao celular descontrolada e método de tratamento de estado doentio ou disfunção associada à proliferação celular descontrolada
BRPI0012352B8 (pt) compostos de indazol ou sal farmaceuticamente aceitável e composição farmacêutica
BR0011585A (pt) Compostos de diaminotiazol,pró-droga farmaceuticamente aceitável,metabólito farmaceuticamente ativo ou sal farmaceuticamente aceitável,composição farmacêutica,método de tratamento de uma condição de doença de mamìferos mediada por atividade de cinase de proteìna e método de modulação da atividade de um receptor de cinase de proteìna
TWI262914B (en) Compounds and pharmaceutical compositions for inhibiting protein kinases
MXPA06001193A (es) Compuestos de indazol 3,5-disustituidos, composiciones farmaceuticas y metodos para intervenir en o inhibir la proliferacion celular.
AR042510A1 (es) Compuestos de indazol y composiciones farmaceuticas para inhibir proteinquinasas y procedimientos para su uso
BRPI0411863A (pt) derivados de pirazolil-indol como inibidores de cinase, processo para seu preparo e composições farmacêuticas compreendendo os mesmos
BR0214112A (pt) Indazolilpirrolotriazinas modificadas c-5
BRPI0411868B8 (pt) derivados de pirrol[3,4-c]pirazol ativos como inibidores de cinase
US8569305B2 (en) Treatment of tuberous sclerosis associated neoplasms
BR0113139A (pt) Compostos, seus sais, formas multiméricas, pró-drogas ou metabólitos, composições farmacêuticas, método de tratamento de uma doença ou disfunção mediana através da inibição de cdk4 ou um complexo de cdk4/ciclina, método de tratamento de condição doentia em mamìferos mediada pela atividade de proteìna cinase e método de modulação ou inibição da atividade de um receptor de proteìna cinase
BR0215063A (pt) Derivados de hidroxifenil-pirazol ativos como inibidores de cinase, processo para preparação dos mesmos e composições farmacêuticas compreendendo-os
ATE246684T1 (de) Substituierte 1,4-dihydroindeno(1,2-c)pyrazole als inhibitoren von tyrosinkinase
CZ255197A3 (cs) Použití 1-{4-[4-aryl (nebo heteroaryl)-1-piperazinyl]butyl}-1H-azolových derivátů pro přípravu léků pro použití při léčení obsedantních neuróz, syndromu spánkové apnoe, sexuálních disfunkcí, zvracení a kinetózy savců, včetně člověka
BR112023025042A2 (pt) Pirrol[2,3-d]pirimidinas substituídas, preparação das mesmas e aplicação terapêutica das mesmas
BR0113258A (pt) Compostos, pró-drogas, metabólitos ou sais, métodos de tratamento de condição doentia em mamìferos, mediada pela atividade de proteìna cinase e métodos de modulação ou inibição da atividade de um receptor de proteìna cinase
BR0016329A (pt) Bis-indolilmaleimidas substituìdas para inibição de proliferação de células
DOP2003000788A (es) Compuestos de indazol y composiciones farmaceuticas para inhibir proteinquinasas, y procedimientos para su uso
UY26543A1 (es) Compuestos, composiciones farmacéuticas de indazol y métodos para mediar o inhibir la proliferación celular.
UY26888A1 (es) Compuestos con núcleos heterocíclicos-hidroximino-fluoreno y las composiciones farmacéuticas para la inhibición de las proteínas cinasas y los métodos para su uso
NZ719050B2 (en) Combination therapy combining a CDK4/6 inhibitor and a PI3K inhibitor for use in the treatment of cancer

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2069 DE 31/08/2010.